OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research report report published on Saturday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

OPGN stock opened at $0.93 on Friday. The business has a 50 day simple moving average of $1.31 and a 200-day simple moving average of $1.93. OpGen has a 1 year low of $0.53 and a 1 year high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.